Advertisement

Topics

Companies Related to "Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers" [Most Relevant Company Matches] RSS

19:33 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers" found in our extensive corporate database of over 50,000 company records.

Showing "Effects CRF1 Receptor Antagonist Human Startle Normal Female" Companies 1–25 of 2,600+

Extremely Relevant

Globe Laboratories

Globe Labs manufactures and sells high quality, low cost human therapeutic proteins, human growth hormones, enzymes, research laboratory cytokines, chemokines & their respective inhibitors/antagonists for research and veterinary use. We are also manufacturers of bulk quantities for other pharmaceutical companies worldwide. Globe Labs is proud to have the largest antagonist product list in the worl...


Relevant

Minerva Biotechnologies

Minerva Biotechnologies is a pioneer in the field of stem cells and cancer stem cells. Minerva was first to discover that cancer cells hijack an otherwise normal stem cell growth mechanism, involving a growth factor receptor called MUC1* (pronounced muk 1 star). By studying human stem cells in parallel with human cancer cells, Minerva scientists figured ou...

AEROVANCE, INC

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing biotherapeutics. The company maintains a solid intellectual property position with its strong portfolio of potential breakthrough products now in clinical development and several pre-clinical programs. The lead products are human recombinant proteins: AEROVANT™, an IL-4 and IL-13 recepto...


Ziarco

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting inflammatory and allergic diseases. The company’s product pipeline includes ZPL-3893787, an H4 receptor antagonist that has completed a Phase 1 multiple ascending dose study. A second clinical-stage, programme targets inflammatory disorders by inhibiting cyto...

Endocyte

Endocyte is developing a new generation of receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases. Current non-targeted drugs are usually toxic to normal healthy cells causing serious side effects. These side effects can be life-threatening which leads to suboptimal dosing. Receptor-targeted therapeutics can be more effective because they can be targete...

Synaptic Pharmaceutical Corporation

Synaptic Pharmaceutical Corporation is a biotechnology company engaged in the development of a broad platform of enabling technology which it calls "human receptor- targeted drug design technology." The Company is utilizing this technology to discover and clone the genes that code for human receptor subtypes that may be associated with specific disorders. The Company and its collaborative part...

Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is distributed primarily by public health organizations and donor groups in about 100 countries around the world. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in Europe, Canada, Australia, South Africa and Japan and ar...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

The Institute for Female Pelvic Medicine & Reconstructive Surgery

The Institute for Female Pelvic Medicine & Reconstructive Surgery is a center for excellence for the comprehensive evaluation and management of female pelvic health, integrating effective medical training, innovative clinical research and service-oriented patient care.

Ebixa

Ebixa is an effective, safe and well tolerated therapy, that helps overcome the everyday challenges in Alzheimer’s disease, easing the lives of both patients and their carers. Ebixa is indicated for the treatment of moderate to severe Alzheimer’s disease. Ebixa is a specific, uncompetitive NMDA-receptor antagonist, with a novel mechanism of action that targets the glutamatergic signalling in ...

Angstrom Pharmaceuticals Incorporated

Ångstrom Pharmaceuticals, Inc. was formed in 1996 to add a new dimension to drug discovery. It is committed to discovering drugs that block the docking of an extracellular regulatory protein (ligand) to its receptor found on the outside of a cell – when this event is responsible for initiating a disease state. Receptors can be identified that trigger several intractable diseases including cance...

CytoDyn Inc.

CytoDyn is a biotechnology company focused on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The Company has one of the leading mAbs under development for HIV infection PRO 140 which is a Late Stage II humanized mAb with dem...

Human Protein Atlas (HPA)

The protein atlas contains histological images from sections of human tissue. These images are equivalent to what is seen in a microscope when examining sections of tissue on glass slides. Each antibody in the database has been used for immunohistochemical staining of both normal and cancer tissue. The immunohistochemical protocols used result in a brown-black staining, localized where an antibody...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, is an oral histamine H4 receptor antagonist, currently in two Phase 2a studies: the first in atopic dermatitis is fully recruited and will read out in Q2 2016; and the second has ...

Veru Healthcare

Veru Healthcare/The Female Health Company is a pharmaceutical and a medical device company that develops and manufactures products for men’s and women’s health and oncology, including the FC2 Female Condom® now available by prescription in the U.S. The Female Health Company division exclusively markets the FC2® into global public health sec...

Limerick BioPharma, Inc.

Limerick BioPharma (http://www.limerickbio.com) is developing small molecule modulators of cell membrane-bound transporters to rid cells of unwanted toxins. By activating cellular transport pumps to redistribute drugs away from organs and tissues where they have adverse effects, the company’s proprietary Activators minimize toxic side effects at non-t...

Zebra Biologics Inc.

Zebra’s mission is the commercialization of human therapeutic antibodies derived by a novel approach that allows the generation and selection of both agonist and antagonist antibodies from functional screens using a modified combinatorial library approach. This new approach was developed at The Scripps Research Institute (TSRI), San Diego, in the laboratory ...

TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migr...

PromoCell

Supplier of normal human cells and cell culture media.

Biofem, Inc

Biofem is a development stage biopharmaceutical company, focused on novel, targeted-delivery therapies for the treatment and prevention of vaginal sexually transmitted diseases in women. Biofem's novel, product, along with its patented technology for the delivery of normal microorganisms, has allowed it to develop a unique product that crosses multiple areas of female sexually transmitted diseases...

ChemoCentryx, Inc.

ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available medicines for autoimmune diseases, inflammatory disorders and oncology. By leveraging our pioneering expertise in the field of chemokine research, ChemoCentryx has generated a broad portfolio of medicines targeting the chemokine system, with six product candidates currently in pre-clinical and clinical stage...

Arcus Biosciences, Inc.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an an...

Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the companyâ€...

ActoKine Therapeutics

Cancer therapy using cytotoxic drugs or radiation has negative side effects on normal cells. To date, the pharmaceutical industry has not been able to produce a drug that can provide the dual functions of protecting normal cells while sensitizing tumor cells to cancer therapy. With consultation and guidance from industry experts, ActoKine will collaborate with international drug companies and inst...


More From BioPortfolio on "Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks